



Publication of a shareholder newsletter

Paris, October 4th, 2016 - ABIVAX (Euronext Paris : FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease, today announces the publication of a shareholder newsletter that provides an update on the major achievements of the first half of 2016. The Shareholder Newsletter is available on the website at: www.abivax.com (Investors and Investor Presentation).

About ABIVAX (www.abivax.com)

ABIVAX is an innovative biotechnology company focused on targeting the immune system to eliminate viral disease. ABIVAX leverages three technology platforms for drug discovery: an anti-viral, an immune enhancement, and a polyclonal antibody platform. ABX464, its most advanced compound, is currently in Phase II clinical trials and is a first-in-class oral small anti-viral molecule which blocks HIV replication through a unique mechanism of action. In addition, ABIVAX is advancing multiple preclinical candidates against additional viral targets (i.e. Chikungunya, Ebola, Dengue) as well as an immune enhancer, and several of these compounds are planned to enter clinical development within the next 18 months. A recently updated corporate presentation, which includes a timeline for the company's anticipated news flow, is available at www.abivax.com.

Follow us on Twitter @ABIVAX

Contacts

Finance

Alain Chevallier
Alain.chevallier@abivax.com
+33 1 53 83 08 41

Press Relations

ALIZE RP
Caroline Carmagnol/Margaux Pronost
abivax@alizerp.com
+33 6 64 18 99 59 / +33 1 44 54 36 65

Citigate Dewe Rogerson

Antoine Denry/Alexandre Dechaux
abivax@citigate.fr
+33 1 53 32 84 75

LifeSci Advisors

Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254